Bristol-Myers Squibb Co (NYSE:BMY)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $60.30, but opened at $58.90. Bristol-Myers Squibb shares last traded at $55.98, with a volume of 13606732 shares changing hands.

Several research firms have commented on BMY. Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, July 15th. ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Atlantic Securities raised shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 target price on the stock in a report on Wednesday, August 8th. Barclays raised their target price on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Friday, October 12th. Finally, Credit Suisse Group reissued a “hold” rating and issued a $61.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, September 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $63.13.

The firm has a market cap of $91.50 billion, a PE ratio of 18.04, a P/E/G ratio of 1.50 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.28 and a current ratio of 1.40.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.74 EPS. On average, equities analysts predict that Bristol-Myers Squibb Co will post 3.64 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Friday, October 5th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 2.95%. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

A number of large investors have recently bought and sold shares of the stock. Wealth Architects LLC lifted its position in shares of Bristol-Myers Squibb by 14.0% in the 3rd quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 848 shares during the period. Beech Hill Advisors Inc. lifted its position in shares of Bristol-Myers Squibb by 0.8% in the 3rd quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock worth $6,549,000 after purchasing an additional 850 shares during the period. Signature Financial Management Inc. lifted its position in shares of Bristol-Myers Squibb by 1.9% in the 2nd quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock worth $2,546,000 after purchasing an additional 870 shares during the period. DnB Asset Management AS lifted its position in shares of Bristol-Myers Squibb by 0.3% in the 2nd quarter. DnB Asset Management AS now owns 321,762 shares of the biopharmaceutical company’s stock worth $17,806,000 after purchasing an additional 900 shares during the period. Finally, Mcmillion Capital Management Inc. lifted its position in shares of Bristol-Myers Squibb by 1.4% in the 2nd quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock worth $3,544,000 after purchasing an additional 903 shares during the period. Institutional investors and hedge funds own 72.32% of the company’s stock.

Bristol-Myers Squibb Company Profile (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: How to interpret a stock’s beta number

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.